Trials / Terminated
TerminatedNCT00679484
Study to Demonstrate the Non-inferiority of Olmesartan Medoxomil Versus Candesartan Cilexetil in Reducing Blood B-type (or Brain) Natriuretic Peptide Levels at Week 24
A 24-Week Multicentre, Randomized, Double-Blind, Controlled, Parallel Group Non-Inferiority Study to Assess the Efficacy and Safety of Olmesartan Medoxomil Versus Candesartan Cilexetil in Patients With Symptomatic Heart Failure (NYHA II-IV)
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- Sponsor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This study will compare olmesartan medoxomil to candesartan cilexetil in reducing BNP, a prognostic biomarker of heart failure, at week 24
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | olmesartan medoxomil + candesartan cilexetil placebo | Dosage form: tablet; frequency: daily; duration: 24 weeks |
| DRUG | olmesartan medoxomil placebo + candesartan cilexetil | Dosage form: tablets; frequency: daily; duration: 24 weeks |
Timeline
- Start date
- 2008-06-01
- Primary completion
- 2009-11-01
- Completion
- 2009-11-01
- First posted
- 2008-05-16
- Last updated
- 2018-12-24
Locations
11 sites across 3 countries: France, Germany, Netherlands
Source: ClinicalTrials.gov record NCT00679484. Inclusion in this directory is not an endorsement.